pubmed-article:16271099 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:16271099 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:16271099 | lifeskim:mentions | umls-concept:C0014792 | lld:lifeskim |
pubmed-article:16271099 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
pubmed-article:16271099 | lifeskim:mentions | umls-concept:C2350458 | lld:lifeskim |
pubmed-article:16271099 | lifeskim:mentions | umls-concept:C0524727 | lld:lifeskim |
pubmed-article:16271099 | lifeskim:mentions | umls-concept:C0282461 | lld:lifeskim |
pubmed-article:16271099 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
pubmed-article:16271099 | lifeskim:mentions | umls-concept:C0450254 | lld:lifeskim |
pubmed-article:16271099 | lifeskim:mentions | umls-concept:C2348767 | lld:lifeskim |
pubmed-article:16271099 | pubmed:issue | 11 | lld:pubmed |
pubmed-article:16271099 | pubmed:dateCreated | 2005-11-7 | lld:pubmed |
pubmed-article:16271099 | pubmed:abstractText | A randomized, double-blind trial is reported of the clinical efficacy of red blood cells (RBCs) treated for pathogen inactivation with S-303, a synthetic labile alkylating agent. | lld:pubmed |
pubmed-article:16271099 | pubmed:language | eng | lld:pubmed |
pubmed-article:16271099 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16271099 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:16271099 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16271099 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16271099 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16271099 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16271099 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:16271099 | pubmed:month | Nov | lld:pubmed |
pubmed-article:16271099 | pubmed:issn | 0041-1132 | lld:pubmed |
pubmed-article:16271099 | pubmed:author | pubmed-author:MintzPaul DPD | lld:pubmed |
pubmed-article:16271099 | pubmed:author | pubmed-author:BenjaminRicha... | lld:pubmed |
pubmed-article:16271099 | pubmed:author | pubmed-author:SpotnitzWilli... | lld:pubmed |
pubmed-article:16271099 | pubmed:author | pubmed-author:RizzoRobert... | lld:pubmed |
pubmed-article:16271099 | pubmed:author | pubmed-author:McCulloughJef... | lld:pubmed |
pubmed-article:16271099 | pubmed:author | pubmed-author:WagesDavidD | lld:pubmed |
pubmed-article:16271099 | pubmed:author | pubmed-author:CorashLaurenc... | lld:pubmed |
pubmed-article:16271099 | pubmed:author | pubmed-author:SnyderEdwardE | lld:pubmed |
pubmed-article:16271099 | pubmed:author | pubmed-author:LinJin-SyingJ... | lld:pubmed |
pubmed-article:16271099 | pubmed:author | pubmed-author:ConlanMaureen... | lld:pubmed |
pubmed-article:16271099 | pubmed:author | pubmed-author:WoodLindseyL | lld:pubmed |
pubmed-article:16271099 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:16271099 | pubmed:volume | 45 | lld:pubmed |
pubmed-article:16271099 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:16271099 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:16271099 | pubmed:pagination | 1739-49 | lld:pubmed |
pubmed-article:16271099 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
pubmed-article:16271099 | pubmed:meshHeading | pubmed-meshheading:16271099... | lld:pubmed |
pubmed-article:16271099 | pubmed:meshHeading | pubmed-meshheading:16271099... | lld:pubmed |
pubmed-article:16271099 | pubmed:meshHeading | pubmed-meshheading:16271099... | lld:pubmed |
pubmed-article:16271099 | pubmed:meshHeading | pubmed-meshheading:16271099... | lld:pubmed |
pubmed-article:16271099 | pubmed:meshHeading | pubmed-meshheading:16271099... | lld:pubmed |
pubmed-article:16271099 | pubmed:meshHeading | pubmed-meshheading:16271099... | lld:pubmed |
pubmed-article:16271099 | pubmed:meshHeading | pubmed-meshheading:16271099... | lld:pubmed |
pubmed-article:16271099 | pubmed:meshHeading | pubmed-meshheading:16271099... | lld:pubmed |
pubmed-article:16271099 | pubmed:meshHeading | pubmed-meshheading:16271099... | lld:pubmed |
pubmed-article:16271099 | pubmed:meshHeading | pubmed-meshheading:16271099... | lld:pubmed |
pubmed-article:16271099 | pubmed:meshHeading | pubmed-meshheading:16271099... | lld:pubmed |
pubmed-article:16271099 | pubmed:meshHeading | pubmed-meshheading:16271099... | lld:pubmed |
pubmed-article:16271099 | pubmed:meshHeading | pubmed-meshheading:16271099... | lld:pubmed |
pubmed-article:16271099 | pubmed:meshHeading | pubmed-meshheading:16271099... | lld:pubmed |
pubmed-article:16271099 | pubmed:meshHeading | pubmed-meshheading:16271099... | lld:pubmed |
pubmed-article:16271099 | pubmed:meshHeading | pubmed-meshheading:16271099... | lld:pubmed |
pubmed-article:16271099 | pubmed:meshHeading | pubmed-meshheading:16271099... | lld:pubmed |
pubmed-article:16271099 | pubmed:meshHeading | pubmed-meshheading:16271099... | lld:pubmed |
pubmed-article:16271099 | pubmed:year | 2005 | lld:pubmed |
pubmed-article:16271099 | pubmed:articleTitle | Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. | lld:pubmed |
pubmed-article:16271099 | pubmed:affiliation | Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. benjaminr@usa.redcross.org | lld:pubmed |
pubmed-article:16271099 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:16271099 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
pubmed-article:16271099 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:16271099 | pubmed:publicationType | Multicenter Study | lld:pubmed |
pubmed-article:16271099 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16271099 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16271099 | lld:pubmed |